Breast Cancer Rate in Men Rises
Breast Cancer Rate in Men Rises
Breast Cancer Rate in Men Rises
As breast cancer rate in men rises, US FDA encouraged drug companies saying men’s breast cancer
should also be included in studies last August 2019.
From 0.85 per 100,000 men United States in 1975 to 1.21 per 100,000 men in 2016, breast cancer rate
in men has risen to an estimated 2,670 men in United States this year.
The study in JAMA Oncology found out that women has higher survival rates than men after three and
five year of diagnosis. This means that men are more likely to die due to cancer.
Besides, men makes up less 1 percent in breast cancer cases, unlike in woman who makes the rest of the
cases.
With registered case of 1,816,733 U.S. diagnosed patients from January 2004 until December 2014,
16,025 of it were identified to be men’s case.
Somehow, men find it slightly unfair beacuse woman have more advantage to find symptoms of breast
cancer earlier by doing regular breast exams.
“The most striking thing is that there was a difference in treatment.” Laura Esserman, a breast
oncologist at the University of California, San Francisco expressed.
84.5 percent of the male breast cancer patients’ tumor grow in response to estrogen or progesterone
yet, only 57.9 percent received therapy that stops the growth of cancer cells. The remaining percent
belongs to the patients who were “hormone-receptor positive”.
Fortunately, men could take follow-up treatment and after this, patients were adviced to take
“Tamoxifen”, a pill that reduces risk of cancer recurrence. According to the experts, this pill has side
effects like mood swings, nausea, hot flashes and loss of sex drive.
Yet, hormone therapies in women might not work in men due to different molecular pathways says
Xiaoxian Bill Li, a breast pathologist at Emory University in Atlanta.
To expand the studies and treatment options that could help male breast cancer patients, US Food and
Drug Administration encouraged drug companies and manufacturers to study men’s condition as well.
The request has been approved by an agency but no male participants were included by the reason of
the drug’s behavior between the sexes.